Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$141.23 USD

141.23
854,657

-4.55 (-3.12%)

Updated Jun 10, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923

by Zacks Equity Research

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.

BOLT Enters Into a Collaboration Agreement With Bristol Myers

by Zacks Equity Research

BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.

Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED

by Zacks Equity Research

Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.

RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

by Zacks Equity Research

Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.

Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree

by Zacks Equity Research

The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.

Takeda (TAK) Hematology Candidate Fails in Late-Stage Study

by Zacks Equity Research

Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.

Roche (RHHBY) Withdraws Tecentriq for Breast Cancer in the U.S.

by Zacks Equity Research

Roche (RHHBY) will withdraw Tecentriq for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer in the United States.

BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.

Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug

by Zacks Equity Research

Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.

Repligen (RGEN) Up 16.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine

by Zacks Equity Research

Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.

Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug

by Zacks Equity Research

FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.

CARA Drug Wins FDA Nod for Pruritus Associated With CKD

by Zacks Equity Research

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

AstraZeneca (AZN) Stops Phase III Study on Ultomiris for ALS

by Zacks Equity Research

AstraZeneca (AZN) stops the phase III CHAMPION-ALS study on Ultomiris for treating adults with amyotrophic lateral sclerosis, following a recommendation from the Independent Data Monitoring Committee.

Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review

by Zacks Equity Research

Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.

J&J (JNJ) CEO Alex Gorsky to Resign, Joaquin Duato to Succeed

by Zacks Equity Research

J&J's (JNJ) CEO Alex Gorsky who has led the company for almost a decade resigns. Joaquin Duato to succeed as CEO.

Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.

Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study

by Zacks Equity Research

Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.

AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints

by Zacks Equity Research

AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.

Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication

by Zacks Equity Research

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.

Mei (MEIP) Begins Phase III Study for B-Cell Malignancies

by Zacks Equity Research

Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.

Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline

by Zacks Equity Research

Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

by Zacks Equity Research

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

by Zacks Equity Research

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement

by Zacks Equity Research

Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.